We discovered that lenalidomide, at a clinically achievable concentration [16, 32], prevented the suppression of IL-2-mediated activation of NK cell cytotoxicity, ADCC, and IFNγ secretion by neuroblastoma/monocyte CM. Here, IFNG is linked to neuroblastoma.